XML 33 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Loss

The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Chronic cough in IPF clinical trial expense

 

$

4,347

 

 

$

3,039

 

 

$

6,034

 

 

$

5,921

 

Refractory chronic cough clinical trial expense

 

 

2,028

 

 

 

434

 

 

 

3,106

 

 

 

1,252

 

Clinical trial material

 

 

2,351

 

 

 

330

 

 

 

3,904

 

 

 

564

 

Other clinical trials and studies 1

 

 

1,144

 

 

 

1,269

 

 

 

2,443

 

 

 

1,317

 

Other clinical development expenses 2

 

 

1,848

 

 

 

1,861

 

 

 

3,371

 

 

 

3,279

 

Employee compensation (excluding stock compensation expense)

 

 

3,347

 

 

 

2,818

 

 

 

6,506

 

 

 

5,775

 

Stock-based compensation expense

 

 

3,272

 

 

 

1,384

 

 

 

5,463

 

 

 

2,592

 

Other segment items 3

 

 

2,156

 

 

 

2,573

 

 

 

4,554

 

 

 

4,473

 

Interest income, net

 

 

(2,696

)

 

 

(1,407

)

 

 

(4,392

)

 

 

(2,532

)

Net loss

 

$

17,797

 

 

$

12,301

 

 

$

30,989

 

 

$

22,641

 

 

(1) Includes expense related to the Company’s Phase 1 NDA supportive studies

(2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.

(3) Includes general administrative expense, other (expense) income, net and income tax benefit.